Physician profile
Bryan G Johnson
NPI 1154340925
$7,770.81
in general payments reported to CMS, 2019-2025
53 companies · $754 in 2025
The $754 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $1,322 · 2021: $1,465 · 2022: $1,190 · 2023: $1,082 · 2024: $1,174 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $804.31 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $665.98 | 2021-2025 | |
| Novo Nordisk INC | $606.36 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $605.46 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.23 | 2019-2025 | Jardiance |
| Pfizer INC. | $435.96 | 2019-2024 | |
| Abbott Laboratories | $402.35 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $343.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $311.36 | 2019-2025 | Jardiance, Kisunla, Mounjaro |
| Antares Pharma, INC. | $277.05 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $253.97 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $208.25 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $204.19 | 2019-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $160.63 | 2019-2023 | Xarelto |
| Arbor Pharmaceuticals, INC. | $142.75 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.